Aldeyra Therapeutics (ALDX)
ALDX · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Ophthalmologysrc
Signal Snapshot
1
Clinical Trial (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
1 Phase 3
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema. — Ophthalmol Ther (2026) PMID 42771326
- Improvement in Visual-Tasking Daily Living Activities and Work Productivity in Patients with Dry Eye Disease: Integrated Analysis of COMET Studies. — Ophthalmol Ther (2026) PMID 42470519
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Aldeyra Therapeutics.
Full ALDX Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.